Oral contraceptives recalled

Article

An immediate voluntary recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets?about 1 million packets?was issued on February 1 by Pfizer after an internal investigation reported that some of the blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence, increasing the risk of an unintended pregnancy among women using the pills for contraception.

An immediate voluntary recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets-about 1 million packets-was issued on February 1 by Pfizer after an internal investigation reported that some of the blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence, increasing the risk of an unintended pregnancy among women using the pills for contraception.

Pfizer notified the US Food and Drug Administration, healthcare providers, and consumers of the recall on February 1.

Akrimax Pharmaceuticals distributed the product to warehouses, clinics, and retail pharmacies throughout the United States. The pills are sold in packs containing 21 tablets of active ingredients and 7 tablets with inactive ingredients. Expiration dates printed on the affected lots are from July 31, 2013 through March 31, 2014.

A complete list of lot numbers for the branded and generic formulations is posted at http://www.fda.gov/Safety/Recalls/ucm289770.htm. FDA and Pfizer advise women who have packets of pills in the affected lots to notify their physicians, return the product to the pharmacy, and begin using a second form of birth control immediately.

Read other articles in this issue of Special Delivery.

Recent Videos
Self-collection and extended genotyping advance cervical cancer screening | Image Credit: linkedin.com.
New trends in cervical cancer screening: Self-collection and barriers to adherence | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
Related Content
© 2025 MJH Life Sciences

All rights reserved.